Skip to main content

$0.007 (0%)

High

$0.01

Low

$0.01

Trades

47

Turnover

$23,686

Volume

3,636,136
30 June 2023 at 4:10pm
Register to track ME1 and receive email alerts.

Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser. In addition, the company develops Halucenex, which is in phase II clinical trials, which will test the efficacy of psilocybin on treatment of resistant Post Traumatic Stress Disorder. Further, it engages in marketing of its hemp based food, feed supplements, and topical products; manufacture and sale of packaged consumer products; conducts clinical trial and development of synthetic psilocybin micro and macro dose formulations to treat treatment resistant depression and anxiety; and development of psychedelic medicines. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Expand Company Description

Please note that we source our information from many sources. The below may not be accurate, or up to date. Please bear with us whilst we fine tune our data collection. In the meantime, we do not recommend relying on the below. It is merely a guide!

Information on this page was last updated around 18 April 2024.

Stock Information

Code

ME1

Name

Melodiol Global Health Ltd.

Country

AU

Currency

AUD

GIC Sector

Health Care

GIC Group

Pharmaceuticals, Biotechnology & Life Sciences

GIC Industry

Pharmaceuticals

GIC Sub Industry

Pharmaceuticals

Sector

N/A

IPO Date

N/A

Fiscal Year

December

Type

Common Stock

Shares Outstanding

281,870,016

Shares Floated

314,636,594

Held by Insiders

21.514%

Held by Institutions

0.003%

Technicals

52w High

$0.44

52w Low

$0.00

50D MA

$0.01

200D MA

$0.07

Financial Snapshot (June 2023)

Market Cap (18-Apr)

$1,127,480

EBITDA

-

PE

0.00

Book Value

$-0.02

Dividend per Share

N/A

Dividend Yield

N/A

EPS

$-0.60

Profit Margin

N/A

Operating Margin

-80.32%

ROA

33.31%

ROE

389.56%

Revenue (FY)

$18,921,000

Revenue per Share

$0.14

Gross Profit (FY)

$0

Q' YOY Revenue Growth

-

Q' YOY Earnings Growth

-

Directors & Officers

Name & Education Position

Mr. Boaz Wachtel M.A., M.D., MBA

Co-Founder & Non-Executive Chairman

Mr. William Lay B.Com.

Group CEO, MD & Director

Mr. Christopher Grundy BCom, FCA, FCIS, GAICD

Chief Financial Officer

Ms. Micheline MacKay B.Sc., M.Sc., P.M.P.

Executive Director

Dr. Gian Trepp

Commercial & Marketing Director

Mr. Mitchel Fleming

Managing Director of Halucenex

Brett Ayers

Managing Director of Impactive

Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom

Joint Company Secretary

Hon. Brian Walker

Strategic Consultant & Chair of Scientific Advisory Committee

ME1 Historic Dividends

Date Amount
We found no dividends on record for ME1.
Register to track ME1 and receive email alerts.